A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and
efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.